Wednesday, June 19, 2019 Daily Archives

Lonza building capacity for Gamida’s bone marrow transplant

by

Lonza will construct suites at its site in The Netherlands dedicated to producing Phase III and commercial supply of Gamida’s bone marrow transplant cell therapy omidubicel. Lonza has produced clinical supply of omidubicel for Gamida but the strategic deal announced today will see the Swiss contract development and manufacturing organization (CDMO) fulfil the future commercial supply from its site in Geleen, The Netherlands. Formerly known as NiCord, omidubicel is the Massachusetts-based cell therapy firm’s lead candidate, currently in Phase III…

June 19, 2019

Single-Use Systems: Globalization Best Practices and Technology Specifications

by

The challenges of multi-national bioprocessing operations are numerous. They include finding highly skilled experts for each site, lack of expertise with single-use systems, contamination risks and redundant efforts and resources—all of which can lead to higher costs. But these challenges also present opportunities for increasing speed to market, eliminating redundant work and overall cost savings. This white paper details the best practices used in global drug manufacturing. The key is global coordination. Best practices and specifications need to be identified…

June 19, 2019

Long RNA Synthesis Report

by

Long single-stranded RNA oligonucleotides are increasingly necessary for a variety of genomic pathway research and drug discovery studies. However synthesizing and purifying long RNAs can pose unique challenges due to their sequence composition, secondary structure, and applied modifications. Here we explore how Horizon Discovery is leveraging Dharmacon’s 20+ years of RNA synthesis experience to solve the challenges of long RNA oligo synthesis to address unmet research needs.

June 19, 2019

Celgene pays BeiGene $150m as it hands back anti-PD-1 rights

by

Ahead of its acquisition by Bristol-Myers Squibb, Celgene has agreed to hand back the development and commercialization rights of solid tumor candidate tislelizumab to Chinese drugmaker BeiGene. In August 2017, BeiGene inked a deal to acquire Celgene’s commercial operations and portfolio assets in China while handing over the exclusive rights to develop and commercialize its investigational anti-PD1 antibody, BGB-A317 (tislelizumab) for solid tumors outside of the region. But in a report filed with the SEC yesterday, BeiGene said the two…

June 19, 2019